These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38881525)

  • 1. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.
    Brandariz-Núñez D; Luances-Rodríguez A; Feijoo-Vilanova P; Gutiérrez-Urbón JM; Ramudo-Cela L; Martín-Herranz MI; Margusino-Framiñán L
    Rev Esp Quimioter; 2024 Aug; 37(4):334-340. PubMed ID: 38881525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
    Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
    Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
    Hidalgo-Tenorio C; Sadyrbaeva-Dolgova S; Enríquez-Gómez A; Muñoz P; Plata-Ciezar A; Miró JM; Alarcón A; Martínez-Marcos FJ; Loeches B; Escrihuela-Vidal F; Vinuesa D; Herrero C; Boix-Palop L; Del Mar Arenas M; Vázquez EG; de Las Revillas FA; Pasquau J;
    Int J Antimicrob Agents; 2023 Sep; 62(3):106918. PubMed ID: 37442488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin for treating enterococcal infective endocarditis: A retrospective observational study from a referral centre in Spain.
    Escolà-Vergé L; Fernández-Hidalgo N; Rodríguez-Pardo D; Pigrau C; González-López JJ; Bartolomé R; Almirante B
    Int J Antimicrob Agents; 2019 Feb; 53(2):165-170. PubMed ID: 30315920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin for infective endocarditis: a single centre experience.
    Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
    J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
    Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin in clinical practice: a particular place for the elderly?
    Wackenheim C; Le Maréchal M; Pluchart H; Gavazzi G; Blanc M; Caspar Y; Pavese P;
    Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):977-979. PubMed ID: 35471751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
    Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
    Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
    Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Ramharter M; Steininger C; Vossen MG; Winkler S; Thalhammer F
    Clin Infect Dis; 2018 Aug; 67(5):795-798. PubMed ID: 29659732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid for infective endocarditis: A structured approach based on a national database experience.
    Muñoz P; De la Villa S; Martínez-Sellés M; Goenaga MA; Reviejo-Jaka K; Revillas FAL; García-Cuello L; Hidalgo-Tenorio C; Rodríguez-Esteban MA; Antorrena I; Castelo-Corral L; García-Vázquez E; De la Torre J; Bouza E;
    Medicine (Baltimore); 2021 Dec; 100(51):e27597. PubMed ID: 34941026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.
    Lalanne S; Cattoir V; Guerin F; Verdier MC; Revest M
    J Antimicrob Chemother; 2023 Jul; 78(7):1689-1693. PubMed ID: 37248684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study.
    Cervera C; del Río A; García L; Sala M; Almela M; Moreno A; Falces C; Mestres CA; Marco F; Robau M; Gatell JM; Miró JM;
    Enferm Infecc Microbiol Clin; 2011 Oct; 29(8):587-92. PubMed ID: 21723004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
    Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
    Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.